Print

MediGene, Inc. Drug Extends Pancreatic Cancer Survival  
9/16/2008 6:47:17 AM

LONDON, Sept 16 (Reuters) - Patients with inoperable pancreatic cancer live substantially longer when given MediGene's experimental drug EndoTAG-1 on top of standard chemotherapy, according to clinical trial results.
//-->